Page 14 | Certara

On-Demand Webinar

Certara’s Simcyp Educational Webinar Series: Learn from A to Z of PBBM Part 2: What is the Drug Absorption Model?

Part 3 in November: Understanding the Supersaturated Dissolution in the Digestive Tract with Modeling &…

CertaraMay 12, 2025

Conference

2025 SNMMI Annual Meeting

CertaraMay 9, 2025

Blog

QSP Summit 2025: A New Standard in the Future of Drug Development

May 5, 2025 The Quantitative Systems Pharmacology (QSP) Summit 2025, hosted by Certara, marked another…

CertaraMay 5, 2025

Press Release

Certara Reports First Quarter 2025 Financial Results

RADNOR, PA— May 5, 2025-- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development,…

CertaraMay 5, 2025

On-Demand Webinar

Explore First: How a Stepwise Approach to QTc Studies Reduces Time, Cost, and Regulatory Risk

Learn how a stepwise C-QTc approach can streamline cardiac safety evaluation, reduce costs, and align…

CertaraMay 5, 2025

Blog

Essentials of Model-informed Drug Development in Oncology

Model-informed drug development in oncology is critical to developing safer and more effective cancer drugs.…

CertaraMay 2, 2025

Live Events

Annual European Futbol Pharmacometrics Collective

Date: Wednesday, June 4Time: 6:00 PM – 10:00 PMLocation: Football Sport Center — 47 Poseidonos…

CertaraMay 1, 2025

Publication

A translational model-based meta-analysis to predict tremor incidence associated with serotonin reuptake transporter inhibition

The serotonin reuptake transporter (SERT) is responsible for the removal and recycling of the neurotransmitter…

CertaraApril 30, 2025

Poster

Clinical validation of a quantitative systems pharmacology (QSP) model of ISB 2001 used for deriving first in human (FIH) dose and efficient phase 1 dose escalation design in relapsed/refractory multiple myeloma (RRMM) patient

In partnership with Ichnos, Certara developed a QSP model to determine the most suitable therapeutic…

CertaraApril 30, 2025

Fact Sheet

Non-Animal Navigator™: Expert strategy and AI-enabled biosimulation to reduce, refine, or replace animal studies

Certara’s Non-Animal Navigator™ solution helps companies adapt by selecting and optimizing the best-fit NAM strategies.

CertaraApril 30, 2025

Certara’s Simcyp Educational Webinar Series: Learn from A to Z of PBBM Part 2: What is the Drug Absorption Model?

2025 SNMMI Annual Meeting

QSP Summit 2025: A New Standard in the Future of Drug Development

Certara Reports First Quarter 2025 Financial Results

Explore First: How a Stepwise Approach to QTc Studies Reduces Time, Cost, and Regulatory Risk

Essentials of Model-informed Drug Development in Oncology

Annual European Futbol Pharmacometrics Collective

A translational model-based meta-analysis to predict tremor incidence associated with serotonin reuptake transporter inhibition

Clinical validation of a quantitative systems pharmacology (QSP) model of ISB 2001 used for deriving first in human (FIH) dose and efficient phase 1 dose escalation design in relapsed/refractory multiple myeloma (RRMM) patient

Non-Animal Navigator™: Expert strategy and AI-enabled biosimulation to reduce, refine, or replace animal studies

Newsletter sign up

Quick links

Solutions

Contact